Get the Stockscreener App
29.54
12.29%
-4.14
Pre-market:
30.00
0.46
+1.56%
Surrozen Inc stock is traded at $29.54, with a volume of 1.93M.
It is down -12.29% in the last 24 hours and up +26.46% over the past month.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
See More
Previous Close:
$33.68
Open:
$34.72
24h Volume:
1.93M
Relative Volume:
4.66
Market Cap:
$347.20M
Revenue:
$7.49M
Net Income/Loss:
$-360.50M
P/E Ratio:
-0.7149
EPS:
-41.3227
Net Cash Flow:
$-33.68M
1W Performance:
+78.49%
1M Performance:
+26.46%
6M Performance:
+13.01%
1Y Performance:
+147.71%
1-Day Range:
$28.55
$37.83
1-Week Range:
$16.14
$37.83
52-Week Range:
$11.39
$37.83
Surrozen Inc Stock (SRZN) Company Profile
Name
Surrozen Inc
Sector
Industry
Phone
650-475-2820
Address
171 OYSTER POINT BLVD, SOUTH SAN FRANCISCO
Compare SRZN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRZN
Surrozen Inc
|
29.54 | 347.20M | 7.49M | -360.50M | -33.68M | -41.32 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Surrozen Inc Stock (SRZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | TD Cowen | Buy |
| Feb-19-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-30-25 | Initiated | H.C. Wainwright | Buy |
| Jan-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-11-21 | Initiated | BofA Securities | Buy |
| Sep-15-21 | Initiated | Guggenheim | Buy |
| Sep-07-21 | Initiated | Stifel | Buy |
View All
Surrozen Inc Stock (SRZN) Latest News
Surrozen Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Surrozen Price Target Raised to $54.00/Share From $44.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation By Investing.com - Investing.com South Africa
H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation - Investing.com
(SRZN) Risk Channels and Responsive Allocation - Stock Traders Daily
DME red flag in Merck Brunello phase III? Surrozen finishes rich - BioWorld News
SRZN Price Today: Surrozen, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com
Top Biotech Stocks To Keep An Eye OnSeptember 24th - MarketBeat
Crude Oil Rises Over 4%; Darden Earnings Miss Views - benzinga.com
Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy - benzinga.com
Surrozen (SRZN) stock doubles as traders focus on IND progress and potential financing milestone - Quiver Quantitative
SRZN Options Volatility — NASDAQ:SRZN - TradingView
SRZN Options Chain — NASDAQ:SRZN - TradingView
Two new option listings and eight option delistings on September 21st - TipRanks
Surrozen, Inc.(NasdaqCM: SRZN) added to S&P Global BMI Index - marketscreener.com
Surrozen at Morgan Stanley conference: eyeing dual-action edge - Investing.com
Surrozen at Morgan Stanley conference: eyeing dual-action edge By Investing.com - Investing.com Canada
(SRZN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Surrozen submits IND to FDA for DME therapeutic - Glance by Eyes On Eyecare
Surrozen at Cantor healthcare conference: eye drug strategy takes shape - Investing.com
Surrozen at Cantor healthcare conference: eye drug strategy takes shape By Investing.com - Investing.com Canada
Guggenheim Names Top Biotechnology Stock Pick By Investing.com - Investing.com India
Surrozen files SZN-8141 IND application for DME - BioWorld News
Guggenheim Names Top Biotechnology Stock Pick - Investing.com
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - markets.businessinsider.com
Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema - marketscreener.com
Surrozen Inc. Warrant (SRZNW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Discipline and Rules-Based Execution in SRZN Response - Stock Traders Daily
Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewswire
Surrozen Inc. Warrant (SRZNW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Surrozen Inc. Warrant (SRZNW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Surrozen Inc. Warrant (SRZNW) Peer Comparison – Compare with Others - Value Research
William Blair Upgrades Surrozen (NASDAQ:SRZN) to "Strong-Buy" - MarketBeat
William Blair Initiates Surrozen at Outperform - marketscreener.com
William Blair initiates Surrozen stock with Outperform rating By Investing.com - Investing.com Canada
William Blair initiates Surrozen stock with Outperform rating - Investing.com
Surrozen (SRZN) Q2 2026 Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Guggenheim Names Top Stock Pick in Biotech Sector By Investing.com - Investing.com Nigeria
LifeSci Capital Maintains Surrozen(SRZN.US) With Buy Rating, Maintains Target Price $46 - Moomoo
SRZN Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers Strong Beat as Stage Remains Pre-Revenue - vinanet.vn
Braidwell group reports 3.9% Surrozen (SRZN) holding in amended 13G filing - Stock Titan
Surrozen (SRZN): Boxer Capital group discloses 8.9% ownership stake in 13G/A - Stock Titan
Liquidity Mapping Around (SRZN) Price Events - Stock Traders Daily
StemPoint Capital reports 5.0% Surrozen (SRZN) stake via shares and warrants - Stock Titan
Analysts Just Made A Massive Upgrade To Their Surrozen, Inc. (NASDAQ:SRZN) Forecasts - simplywall.st
What is HC Wainwright's Estimate for Surrozen Q3 Earnings? - MarketBeat
Surrozen (SRZN): 5AM Ventures group reports 7.8% beneficial ownership stake - Stock Titan
Surrozen: Buy Rating Reiterated as Clinical Roadmap Clarifies and IP Strengthens; Price Target Maintained at $44 - TipRanks
HC Wainwright Reiterates "Buy" Rating for Surrozen (NASDAQ:SRZN) - MarketBeat
H.C. Wainwright reiterates Surrozen stock rating at buy, $44 target - Investing.com India
Surrozen Inc Stock (SRZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):